Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boston Scientific's gross profit for the
three
months ended in Jun. 2026 was $3,848 Mil. Boston Scientific's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was $14,681 Mil.
Boston Scientific (NYSE:BSX) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Boston Scientific had a gross margin of 70.71% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Boston Scientific Gross Profit Related Terms
Boston Scientific Gross Profit Historical Data
* Premium members only.
The historical data trend for Boston Scientific's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Boston Scientific's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boston Scientific Gross Profit vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's Gross Profit distribution charts can be found below:
* The bar in red indicates where Boston Scientific's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $14,681 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Boston Scientific (BSX) has a Gross Profit of $14,681 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Boston Scientific and its competitors.
Is Boston Scientific's Gross Profit too high?
Boston Scientific's current Gross Profit is $14,681 Mil. Overall, Boston Scientific has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's Gross Profit compare to EW and DXCM?
Boston Scientific's Gross Profit of $14,681 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Devices & Instruments company?
A good Gross Profit depends on the Medical Devices & Instruments industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Boston Scientific and its competitors. Boston Scientific's current Gross Profit is $14,681 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Based on GuruFocus' analysis, Boston Scientific (BSX) is currently considered Significantly Undervalued. The stock's GF Value™ is $107.23, compared to a current price of $42.98 — trading 59.9% below its estimated fair value. The current Gross Profit is $14,681 Mil. Boston Scientific's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Boston Scientific (BSX), the current Gross Profit is $14,681 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boston Scientific (BSX) Overvalued in 2026?
Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued.
The current stock price of $42.98 is trading 59.9% below its estimated GF Value™ of $107.23.
GuruFocus considers Boston Scientific to be Significantly Undervalued.
Key valuation signals for BSX:
Gross Profit: $14,681 Mil
GF Value™: $107.23 vs. price of $42.98 (59.9% below fair value)
No single metric tells the full story. See the BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
80GF Score
Get the complete analysis for BSX
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSX has been successfully added to your 
